Key statistics
On Friday, Biomea Fusion Inc (BMEA:NSQ) closed at 8.64, 139.34% above the 52 week low of 3.61 set on Jun 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.69 |
---|---|
High | 8.76 |
Low | 8.37 |
Bid | 8.35 |
Offer | 9.50 |
Previous close | 8.71 |
Average volume | 397.12k |
---|---|
Shares outstanding | 36.21m |
Free float | 27.16m |
P/E (TTM) | -- |
Market cap | 312.86m USD |
EPS (TTM) | -3.90 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
- Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
- Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
- Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
- Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
- Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
- Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
- Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
More ▼